PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
NCT02864030
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
200
Enrollment
OTHER_GOV
Sponsor class
Conditions
Metastatic Breast Cancer
Toxicity
Neurotoxicity
Drug Toxicity
Adverse Drug Event
Interventions
DRUG:
ERIBULIN MESYLATE
Sponsor
Oncologia Medica dell'Ospedale Fatebenefratelli
Collaborators
[object Object]